Novavax
Gaithersburg
About Novavax
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $2.9B
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2025)
- Ticker: nasdaq:NVAX
- Website: novavax.com
- Phone: (240) 268-2000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/novavax-125141 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.